News
We provide the latest news from the world of economics and finance
(RTTNews) - Twist Bioscience Corp. (TWST) and IMIDomics, Inc. announced a multi-program collaboration whereby Twist will utilize its antigen development capabilities and Library of Libraries to conduct antibody discovery activities against targets identified by IMIDomics. IMIDomics is a biotechnology company focused on patient-centric drug discovery for immune-mediated inflammatory diseases. The targets were identified using IMIDomics' Clinical Discovery Engine.
Twist Bioscience Corp. will receive an upfront and project specific fees and will be eligible to receive payments associated with specific clinical and commercial milestones as well as royalty payments on product sales. IMIDomics will receive human antibodies against several of priority targets from Twist.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2026 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@j2t.com
